Erastin: A Selective Ferroptosis Inducer for Cancer Biology Research

Executive Summary: Erastin (B1524, APExBIO) is a well-characterized small molecule that induces ferroptosis, an iron-dependent, non-apoptotic cell death pathway, especially in tumor cells with oncogenic KRAS or BRAF mutations (APExBIO product page). It acts via inhibition of the cystine/glutamate antiporter (system Xc⁻) and modulation of voltage-dependent anion channels (VDAC), causing lethal accumulation of intracellular reactive oxygen species (ROS) (Hu et al. 2020, DOI). Erastin is extensively used in research to interrogate oxidative stress pathways, characterize ferroptotic cell death, and inform therapeutic strategies targeting difficult-to-treat cancers. Its utility is validated by robust, quantitative benchmarks in both cell and animal models. For optimal results, Erastin must be solubilized in DMSO, freshly prepared before each experiment, and used under defined parameters (e.g., 10 μM for 24 h in HT-1080 cells).

Biological Rationale

Ferroptosis is a regulated cell death mechanism reliant on iron and the accumulation of lipid hydroperoxides, distinct from apoptosis or necroptosis (Hu et al. 2020). Erastin catalyzes this process by selectively targeting tumor cells with activating mutations in RAS (HRAS, KRAS) or BRAF, which exhibit heightened sensitivity due to altered redox metabolism (Erastin: A Premier Ferroptosis Inducer). This selectivity is crucial for modeling oncogenic signaling (RAS-RAF-MEK pathway) and testing caspase-independent cell death hypotheses. Unlike classic apoptosis inducers, Erastin’s mechanism is dependent on iron and is unaffected by caspase inhibition, making it a unique tool for dissecting non-apoptotic death pathways (DOI).

Mechanism of Action of Erastin

Erastin exerts its biological effects through two primary mechanisms:

• Inhibition of System Xc⁻: Erastin blocks the cystine/glutamate antiporter (SLC7A11/SLC3A2), reducing cystine import and glutathione synthesis. This leads to decreased glutathione peroxidase 4 (GPX4) activity and accumulation of lethal lipid peroxides (Hu et al. 2020).
• VDAC Modulation: Erastin binds to VDAC2/3 on the mitochondrial outer membrane, promoting mitochondrial dysfunction and increased ROS generation (Erastin: A Breakthrough Ferroptosis Inducer).

Together, these actions disrupt cellular redox homeostasis, leading to an iron-dependent, oxidative, and non-apoptotic mode of cell death. This biochemical pathway is mechanistically distinct from apoptosis (caspase-dependent) and necroptosis (RIPK1/3-dependent).

Evidence & Benchmarks

• Erastin at 10 μM induces >80% cell death in HT-1080 fibrosarcoma cells after 24 hours, with cell death prevented by the ferroptosis inhibitor ferrostatin-1 (Hu et al. 2020, DOI).
• Vitamin D receptor (VDR) activation attenuates both cisplatin-induced and Erastin-induced ferroptotic cell death in HK-2 cells, highlighting the regulatory role of GPX4 (DOI).
• Erastin-induced cell death is iron- and ROS-dependent but not prevented by pan-caspase inhibitors, confirming a caspase-independent pathway (Erastin: A Ferroptosis Inducer Transforming Cancer Biology).
• Erastin is insoluble in water and ethanol but dissolves in DMSO at ≥10.92 mg/mL when gently warmed (APExBIO, product spec).
• Long-term storage of Erastin in solution is not recommended; freshly prepare DMSO stock before use for reproducible results (Erastin: Ferroptosis Inducer for Advanced Cancer Biology).

Applications, Limits & Misconceptions

Erastin is widely used in:

• Ferroptosis research to dissect iron-dependent cell death pathways.
• Cancer biology, especially in models with KRAS or BRAF mutations, to probe sensitivity to oxidative stress (Erastin: A Leading Ferroptosis Inducer).
• Oxidative stress assays to screen for modulators of redox homeostasis.
• Therapeutic hypothesis testing for cancer types resistant to apoptosis-based treatments.

Compared to prior guides (Erastin: A Premier Ferroptosis Inducer), this article clarifies the mechanistic distinction between ferroptosis and other cell death modalities, and updates application benchmarks with recent in vivo and in vitro data.

Common Pitfalls or Misconceptions

• Erastin is not a pan-cytotoxic agent: It is selective for cells with altered redox metabolism, especially those with RAS/BRAF mutations.
• Ferroptosis is iron- and lipid peroxidation-dependent, not caspase-dependent: Caspase inhibitors do not block Erastin-induced cell death.
• Storage stability: Erastin solutions in DMSO degrade over time; always use freshly prepared stock for experiments.
• Solubility limitations: Insoluble in water/ethanol; only use DMSO as solvent at recommended concentrations and warming conditions.
• Not for direct therapeutic use: Erastin is a research tool; its clinical application is not established.

Workflow Integration & Parameters

For optimal results:

• Obtain Erastin (SKU: B1524) from APExBIO (product page).
• Dissolve powder in DMSO at ≥10.92 mg/mL with gentle warming (37°C recommended).
• Use freshly prepared solutions; discard after use to prevent degradation.
• Treat engineered tumor cells (e.g., HT-1080) at 10 μM for 24 h.
• Include ferroptosis inhibitors (e.g., ferrostatin-1) and iron chelators as controls to confirm pathway specificity.
• Assess readouts: cell viability, ROS levels, lipid peroxidation markers (e.g., malondialdehyde), GPX4 expression.

This workflow supports robust, reproducible interrogation of ferroptosis in cancer models and oxidative stress systems.

Conclusion & Outlook

Erastin, as offered by APExBIO, remains a gold-standard ferroptosis inducer for research in cancer biology and oxidative cell death. Its selective targeting of redox-vulnerable tumor cells and well-characterized mechanism of action underpin its value in both fundamental and translational research. Future studies may leverage Erastin’s selectivity to develop new cancer therapies targeting ferroptosis pathways, especially in RAS/BRAF-driven tumors. For detailed application notes and advanced troubleshooting, see Erastin: Ferroptosis Inducer for Advanced Cancer Biology, which this article updates with new mechanistic insights and benchmarks.